SMMT vs. ALNY, GMAB, TEVA, RPRX, BGNE, BMRN, VTRS, UTHR, RDY, and SRPT
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
Summit Therapeutics has a net margin of 0.00% compared to Summit Therapeutics' net margin of -16.58%. Summit Therapeutics' return on equity of 0.00% beat Alnylam Pharmaceuticals' return on equity.
Alnylam Pharmaceuticals received 803 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 57.17% of users gave Summit Therapeutics an outperform vote.
Alnylam Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alnylam Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500.
In the previous week, Summit Therapeutics had 2 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 11 mentions for Summit Therapeutics and 9 mentions for Alnylam Pharmaceuticals. Summit Therapeutics' average media sentiment score of 1.03 beat Alnylam Pharmaceuticals' score of 0.57 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.
Alnylam Pharmaceuticals currently has a consensus target price of $216.19, indicating a potential upside of 41.50%. Summit Therapeutics has a consensus target price of $13.50, indicating a potential upside of 74.87%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Alnylam Pharmaceuticals.
93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Alnylam Pharmaceuticals beats Summit Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
